<0> Teva Pharmaceutical Industries Ltd.IR:215-591-8912or267-468-4281or972 (3) 926-7656orPR:972 (3) 926-7687or215-591-8974 </0>
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that key data from the Company’s multiple sclerosis (MS) franchise will be featured at the 28 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13, 2012. Data presentations will provide new insights on COPAXONE (glatiramer acetate injection), the world’s leading relapsing-remitting multiple sclerosis (RRMS) treatment, and Teva’s investigational oral compound laquinimod, as well as results from the ongoing TOP MS and NARCOMS studies.
"For more than 20, years Teva has been at the forefront of MS research and development focused on providing effective and safe treatments aimed at meeting the needs of patients’ living with this complex, often debilitating disease,” said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer for Teva Pharmaceutical Industries Ltd. “The data being presented at ECTRIMS demonstrate our ongoing commitment to enhancing the treatment experience for RRMS patients and advancing science to assist neurologists in making appropriate treatment decisions, especially as the market continues to evolve.”
In addition to the data being presented at the Congress, Teva will host a satellite symposium, “New Concepts in MS Pathology Shed Light on MS Treatment Approaches” on Thursday, October 11, 2012 from 19:15 - 20:15 CET. Teva will also host a media event for credentialed journalists on Thursday, October 11, 2012 at 12:00 CET focused on advancements made in RRMS and future considerations for treatment.
The multinational randomized, double-blind placebo-controlled Phase III Glatiramer Acetate Low-frequency Administration (GALA) study examined the efficacy, safety and tolerability of an investigational formulation of glatiramer acetate 40 mg/1 ml administered three times a week compared to placebo in a randomized, double-blind placebo-controlled design in patients with RRMS. A late-breaking news parallel session will present detailed clinical data on October 13, 2012, while a poster presentation will analyze baseline patient demographics for this trial. Key posters include:
sensitive to irreversible tissue damagetransfer ratio (MTR) Key posters include:
Results from the Therapy Optimization in Multiple Sclerosis (TOP MS) study, the largest prospective Phase IV study conducted in MS, provide insight into the impact of adherence to therapy as well as the effect of progression of symptoms on MS patients’ health outcomes and daily activities. Presentation of data will show that better adherence to disease-modifying treatment (DMT) was associated with fewer relapses, as measured by the medication possession ratio (MPR). Additionally, independent of non-adherence to therapy, prior use of one or more MS therapies was associated with increased risk of relapse. In terms of MS symptom effects, a separate presentation will show that change in fatigue severity scale (FSS) was observed as a significant predictor of percent time missed from work. Key posters include:
The North American Research Committee on Multiple Sclerosis (NARCOMS) is a global longitudinal MS registry that collects information regarding the long-term effects of DMT among an active database of over 35,000 MS patients. Researchers analyzed data from the registry to describe the disease characteristics of MS patients who have continuously taken the same DMT for a minimum of five years and to evaluate the likelihood of changes in Patient-Determined Disease Steps (PDDS) and Performance Scales (PS). Results will reveal factors that may inform treatment decisions among clinicians. Key posters include:
COPAXONE (glatiramer acetate injection) is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis, including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.
The most common side effects of COPAXONE are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain.
See additional important information at: . For hardcopy releases, please see enclosed full prescribing information.
COPAXONE is now approved in more than 50 countries worldwide, including the United States, Russia, Canada, Mexico, Australia, Israel, and all European countries.
Laquinimod is an oral, once-daily CNS-active immunomodulator with a novel mechanism of action being developed for the treatment of MS. In animal models, laquinimod crosses the blood-brain barrier to potentially have a direct effect on the neurodegenerative processes of MS. The global Phase III clinical development program evaluating oral laquinimod in MS includes two pivotal studies, ALLEGRO and BRAVO. A third Phase III laquinimod trial, CONCERTO, will evaluate two doses of the investigational product (0.6mg and 1.2mg) in approximately 1,800 patients for up to 24 months. The primary outcome measure will be confirmed disability progression as measured by the Expanded Disability Status Scale (EDSS).
In addition to the MS clinical studies, laquinimod is currently in Phase II of development for Crohn's disease and Lupus.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011.